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Abstract 
Purpose: MRI cell tracking can be used to monitor immune cells involved in the 
immunotherapy response, providing insight into the mechanism of action, temporal 
progression of tumour growth and individual potency of therapies. To evaluate whether 
MRI could be used to track immune cell populations in response to immunotherapy, CD8+ 
cytotoxic T cells (CTLs), CD4+CD25+FoxP3+ regulatory T cells (Tregs) and myeloid 
derived suppressor cells (MDSCs) were labelled with superparamagnetic iron oxide (SPIO) 
particles.  
Methods: SPIO-labelled cells were injected into mice (one cell type/mouse) implanted 
with an HPV-based cervical cancer model. Half of these mice were also vaccinated with 
DepoVaxTM, a lipid-based vaccine platform that was developed to enhance the potency of 
peptide-based vaccines.  
Results: MRI visualization of CTLs, Tregs and MDSCs was apparent 24 hours post-
injection, with hypointensities due to iron labelled cells clearing approximately 72 hours 
post-injection. Vaccination resulted in increased recruitment of CTLs and decreased 
recruitment of MDSCs and Tregs to the tumour. We also found that MDSC and Treg 
recruitment was positively correlated with final tumour volume.  
Conclusion: This type of analysis can be used to non-invasively study changes in immune 
cell recruitment in individual mice over time, potentially allowing improved application 
and combination of immunotherapies.   
 
 
 
 
  
 3 
Introduction 
Immunotherapies are one of the fastest growing classes of cancer therapies with the 
potential to rival traditional therapies as frontline cancer treatments (1-3). Their rapid 
adoption has been driven by monoclonal antibodies (4-6), checkpoint inhibitors (7-11) 
and/or cytokine treatments capable of eradicating tumours through manipulation of the 
immune system. Cancer vaccines (12-14) are another type of T cell based immunotherapy 
capable of activating the immune system that are currently in development and undergoing 
clinical testing. 
Cancer progression is routinely monitored using imaging to assess traditional 
clinical outcomes such as tumour size. However, molecular imaging can also be a valuable 
research tool to explore and understand longitudinal molecular mechanisms initiated by 
novel cancer therapies both preclinically and clinically (15-22). A variety of imaging 
modalities (i.e. magnetic resonance imaging (MRI), positron emission tomography (PET), 
or fluorescence) have been used to investigate the effect of these therapies pre-clinically 
(15-22). Fluorescence or bioluminescence optical imaging is common in the context of 
monitoring intensity changes and migration of therapeutics conjugated to fluorescent tags 
or specific cell types genetically modified for bioluminescence. Both are used as reliable 
pre-clinical markers of interest (23-25). However, optical imaging has limited tissue 
penetration depth and spatial resolution and lacks internal anatomy information provided 
by other imaging modalities such as MRI and PET/computed tomography (CT).  
MRI has been extensively used preclinically to explore immunotherapy behaviour 
by tagging individual vaccine components with superparamagnetic iron oxide (SPIO), 
permitting longitudinal tracking of components over time (22). MRI imaging can also be 
used to track specific cell populations labelled with SPIO (26-31). Previous research using 
MRI has achieved in vivo detection and visualization of single cells labelled with SPIO 
(32,33), which has been used to follow metastases originating from single cells visible by 
MRI (34). MRI has also been used to track the migration of cells injected for direct 
therapeutic effect for various diseases, including dendritic and cytotoxic T cell injections 
used as cancer therapies (30,31,35-37). However, rather than evaluate cellular migration 
patterns of a cellular therapy, we are tracking immune cells involved in the cancer immune 
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response, providing insight on the mechanism of action, temporal progression and 
individual potency of immunotherapies. 
Cytotoxic CD8+ T cells (CTLs) are key cells in the fight against cancer (38). 
However, research has demonstrated that CTLs deployed directly as the sole cancer therapy 
have negligible therapeutic anti-tumour response for solid tumours (39). Immune 
suppressor cells, such as regulatory T cells (Tregs) and myeloid derived suppressor cells 
(MDSCs), are recruited by tumours to inhibit the cytotoxic effects of CTLs (40-44). The 
increased presence of Tregs and other suppressor cells are primarily responsible for 
dampening the vaccine-induced immune responses that target antigens over-expressed by 
cancer cells.  
The success of cancer immunotherapies depends heavily on the interplay between 
cytotoxic and suppressive cell populations (41). Monitoring the location and migration of 
these cells during tumour growth and/or following therapy can be critical for a successful 
immunotherapy approach. It facilitates an understanding of the mechanism of action as 
well as efficient assessment of dose levels, booster timing, and the introduction and 
interaction of additional treatments. The present study aims to achieve this using modern 
cell tracking with SPIO and MRI methods. The migration of CTLs has been extensively 
studied during cytotoxic T cell therapies (36,45,46), but limited information is available on 
the migration of MDSCs and Tregs in cancer models. Furthermore, cellular migration 
following an active therapy, such as vaccination, has not been reported.   
In this study, MRI cell tracking was used to monitor the migration and recruitment 
of SPIO-labelled CTLs, Tregs and MDSCs in a HPV16 expressing tumour mouse model 
(C3: (47,48) following immunotherapy.  Cells were tracked in mice that were untreated or 
vaccinated with a peptide-based cancer vaccine in a DepoVaxTM formulation (12). 
DepoVaxTM (DPX) is a novel immunotherapy formulation designed to elicit sustained 
immune responses (12,43,49,50) via prolonged antigen release (21) and proprietary 
adjuvants. The migration of CTLs, Tregs and MDSCs were evaluated in response to either 
the presence or absence of DepoVax immunotherapy at the group level and on an 
individual basis. 
 
Methods 
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Reagents – Sources for all reagents, antibodies, and media recipes can be found in 
supporting materials and Supporting Table S1. 
 
Cancer Cell Line. The murine cervical cancer C3 cell line (47,48) (cryopreserved in fetal 
bovine serum (FBS) +10% DMSO in liquid nitrogen) were obtained from Dr. Martin Kast 
from the University of Southern California. C3 cells were thawed at 37oC, the freezing 
media was removed, and cells were cultured in C3 media at 37oC in a standard incubator 
with 5% CO2.  
 
Vaccine Formulation.  All peptides were synthesized by PolyPeptide Group with >90% 
purity.  The CD8 epitope HPV16 E749-57 (RAHYNIVTF; R9F) and the universal T helper 
peptide TT947-967(FNNFTVSFWLRVPKVSASHLE; F21E), were used in vaccine 
formulations and were prepared as a proprietary DPX formulation (43), referred to herein 
as DPX-R9F. Briefly, a lipid-mixture containing phosphatidyl choline and cholesterol in a 
10:1 ratio (w:w) (Lipoid GmBH), R9F (5 µg/dose), F21E (5 µg/dose), and a proprietary 
polynucleotide based adjuvant (20 µg/dose) were formulated in 40% tert-butanol, 
lyophilized and resuspended in Montanide ISA 51 VG (SEPPIC). R9F is the epitope 
specific to the C3 cancer model. 
 
Tumour Challenge and Vaccination.  C57BL/6 female mice (4-6 weeks old, Charles 
River Laboratories) were housed with food and water ad libitum under filter top conditions. 
C57BL/6 mice were used as both donor and recipient mice for all MRI experiments. 
Experiments involving mice were carried out in accordance with ethics protocols approved 
by the University Committee on Laboratory Animals at Dalhousie University, Halifax, 
N.S., Canada.   
All mice were implanted with 5x105 C3 cells subcutaneously (s.c.) into the left 
flank (study day 0). Mice were either i) untreated (n=13), or ii) vaccinated with DPX-R9F 
(50 µL) 15 days post-implantation (n=13). Vaccines were delivered via a single s.c. 
contralateral immunization (right flank). Tumour sizes were measured with calipers on a 
weekly basis for the first 3 weeks, then bi-weekly using the following formula: 
longest measurement	×	(shortest measurement)2 	÷ 	2. Mice were scanned 24 and 48 
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and 72 hours post-injection and terminated approximately 96 hours post-cell injection. 
Final tumour volumes were determined post mortem. Lymph nodes (LNs), spleen and 
tumour were harvested and frozen in OCT:20% sucrose (2:1, v/v) for 
immunohistochemistry. 
 
CTL Isolation and Labelling. One week prior to cell injections, inguinal, axial, brachial 
and mesenteric LNs were isolated from donor mice that also had tumours and had the same 
treatment as the recipient mice (either control or vaccine). CTLs were isolated from LNs 
via panning. CTLs were enriched by incubation with rat anti-mouse CD4 (25 µg/mL) and 
rat anti-mouse IgG1k (50 µg/mL) at a density of 1x108 cells/mL. Lymphocytes were then 
incubated on a petri dish coated with goat anti-rat IgG (10 µg/mL).  The enriched CTL 
population was cultured in vitro at a density of 5x105 cells/mL in complete RPMI media 
(cRPMI) supplemented with mouse CD28 (1 µg/mL), gentamycin (5 µg/mL), IL-2 (20 
U/mL), and IL-12 (100 ng/mL) in a coated CD3 (2 µg/mL) culture flask to encourage 
cellular proliferation and activation. Cells were monitored over five days and kept at a 
density of 5-10x105 cells/mL. Fresh cRPMI with IL-2 (20 U/mL) was added as nutrients 
were depleted. Two days after CTL isolation, splenocytes were isolated from disease- and 
treatment-matched mice to act as antigen presenting cells (APCs) to CTLs, stimulated with 
LPS (10 µg/mL) and cultured in vitro in C3 media for two days. Splenocytes were then 
treated with mitomycin-c (50 µg/mL) for 20 min, washed thoroughly, added to the CTLs 
culture at a ratio of 1:6 APC:CTLs and incubated with R9F (10 µg/mL) to encourage 
further priming. At day 7, all cells were washed and iron loaded by incubation at a density 
of 3-4 million cells/mL in cRPMI supplemented with IL-2 (100 U/mL) and SPIO (0.1 
mg/mL; 30 nm, Rhodamine B Molday ION, Biopal) for 20-24h.  
  
MDSC isolation and labelling. One day before cell injections, spleens were isolated from 
donor mice that also had tumours and had the same treatment as the recipient mice (either 
control or vaccine). MDSCs were purified from other splenocytes using a magnetic positive 
selection kit with anti-Gr-1 biotinylated antibody and a biotin specific MACS kit (Miltenyi-
Biotec). After isolation, cells were incubated overnight in cRPMI with 0.1 mg/mL of SPIO.  
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Treg cell isolation and labelling. Six days prior to cell injections, inguinal, axial, brachial 
and mesenteric LNs were isolated from donor mice that also had tumours and had the same 
treatment as the recipient mice (either control or vaccine). CD4+ T cells were purified from 
other lymphocytes via positive CD4+ magnetic selection kit (EasySep, Stemcell 
technologies). CD4+ T cells were differentiated into Tregs by incubation for 5 days in 
cRPMI supplemented with IL-2 (500 U/mL), CD28 (1 µg/mL), gentamycin (5 µg/mL), 
TGF-b (5ng/mL; EMD Millipore), and rapamycin (100 nM) in a culture flasks coated with 
2 µg/mL CD3. At day 5, cells were washed and iron loaded by incubation at a density of 
3-4 million cells/mL in cRPMI supplemented with IL-2 (500 U/mL), TGF-b (5 ng/mL), 
rapamycin (100 nM) and SPIO (0.1 mg/mL) for 20-24h. 
 
Cell injection preparation. SPIO-labelled cells (CTLs, Tregs or MDSCs) were washed 
thoroughly and resuspended in HBSS++ with 20 mM HEPES buffer for 200 µL injection 
of either 10 million CTLs (n=10, treated: n=5) or 5 million MDSCs (n=8, treated: n=4) or 
4 million Tregs (n=8, treated: n=4). All cells were injected intravenously into the tail vein 
on day 28. Numbers of injected cells were chosen based on preliminary MRI qualitative 
data. Cells not used for injection were used for a trypan blue viability test and analysed by 
spectrophotometry using a Prussian blue assay (51) to assess iron loading by UV/VIS 
absorbance spectrophotometry (l = 620 nm). Cellular iron was quantified by lysing cells 
overnight in 100 µL of 1M HCl. K4Fe(CN)6 (1N, 100 µL) was then added, resulting in an 
intense blue colour in the presence of iron. The resulting absorbance was compared to a 
calibration curve of known SPIO concentrations.   
 
Cell culture purity assessment by FACS. Purity analysis of the in vitro culture were 
assessed by flow cytometry using cell samples from respective cultures (~2x106 cells) prior 
to SPIO uptake.  All fluorescent antibodies were anti-mouse. CTLs were stained with 
CD8α (CD8)-efluor660, CD3-peridinin-chlorophyll proteins efluor 710 (PerCP), CD4-
phycoerythrin (PE), and CD11c-PE. Treg cells were labelled with CD25-PE, FoxP3-
allophycocyanin (APC), and CD4-PerCP.  MDSCs were labelled with CD11b-PE and Ly-
6G (Gr-1)-efluor660. Before staining, cells were pre-incubated for 10 min in Fc block (rat 
anti-mouse CD16/CD32, clone 2.4G2) then incubated for 30 minutes at 4°C with 
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respective surface markers. Cells were fixed using 2% PFA in PBS. Intracellular FoxP3 
staining was performed by treating cells with 1X permeabilizing buffer (Saponin; 
eBioscience) and staining with FoxP3-APC for 2 hours at 4˚C.  OneComp ebeads 
(eBioscience) were used for isotype controls.  Cells were analysed using a two laser 
FACSCalibur equipped with CellQuest Pro software (BD Biosciences) and set to collect 
5x104 events. Analysis was performed using FCS Express 6 flow software (De Novo 
Software) and all samples were gated for live cells.  CD4+CD25+FoxP3+ Tregs cells were 
further gated for CD4+CD25+ cells then FoxP3+ to properly establish Tregs.   
 
Cell suppression assays. Transgenic C57BL/6 UbC-GFP mice were used for Treg cell 
isolation and culture (described above). Responder CD4+ T cells (Tresp) were isolated from 
LNs from C57BL/6 mice by CD4+ positive selection as described above for Treg cell 
culture. Tresp cells were labelled with the cell proliferation dye efluor670 (0.5 µM; 
eBioscience) following directions by the manufacturer.  Tresps were co-cultured at 1x105 
cells/well in a 96-well plate coated with CD3 with varying ratios of Tregs (Tresp:Tregs = 
1:1, 1:5, and 1:10) in cRPMI supplemented with 1 µg/mL of CD28.  Cells were incubated 
at 37˚C, 5% CO2, for 72 hours.  After harvest, proliferation was determined by flow 
cytometry (as described above) and gated for GFP- efluor670+ cells.  Treg controls were 
also added to the analysis ensuring that the CD4+CD25+FoxP3+ Treg population was >80% 
at day 0.  The suppressive ability of Tregs was assessed by comparison of Tresp at day 0 
to Tresp at day 3. The suppressive ability of MDSCs isolated using this methodology was 
previously assessed in (43). 
 
Data acquisition and MR Imaging. All data were acquired on a 3T magnet equipped with 
a 21 cm i.d. gradient coil (200mT/m; Magnex Scientific, Oxford, UK) interfaced with a 
Varian DD Console (Varian Inc., Palo Alto, CA, USA). A 30 mm i.d. quadrature 
transmit/receive RF coil (Doty Scientific, Columbia, SC, USA), was used to image 
tumours, vaccination sites, and inguinal LNs simultaneously. 
Anatomical images were obtained using a 3D balanced steady-state free precession 
(bSSFP) (52) sequence (repetition time (TR)/echo time (TE) = 8/4 ms, flip angle = 30°,  a 
38.4×25.5×25.5 mm field of view (FOV), 256×170×170 matrix centered on the torso, 150 
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µm isotropic resolution). Four signal averages were acquired with four separate RF phase 
increments to displace and remove off-resonance banding artifacts (52) for a total scan time 
of approximately 64 minutes per animal. Mice received a baseline scan prior to SPIO-
labelled cell injection on study day 27, 24 hours prior to cell injection. Mice were scanned 
24, 48 and 72 hours post-cell injection.  
 
MRI Image Analysis and Statistical Analysis. Volumetric segmentation was performed 
by a single observer, and confirmed by a second independent reviewer.  All images were 
first zero-padded (interpolated to a higher resolution grid to increase the effective 
resolution and image quality) using ImageJ (NIH).  Images were analysed in RView for 
each mouse (53,54).  A semi-automated region growing algorithm (54) was implemented 
to perform individual 3D segmentations to determine tumour volumes, left inguinal LN 
(LLN, tumour draining) and right inguinal LN volumes (RLN, vaccine draining).  
Tumour and lymph node regions of interest (ROIs) were hand-drawn in VivoQuant 
(Invicro) and verified by a separate reviewer. At each time point, the 3D tumour and lymph 
node ROIs encompassed the entire tissue structure of interest (i.e. tumour ROIs consisted 
of the entire tumour) to minimize difference due to positional changes. ROI histograms 
were extracted and cell recruitment was assessed by integrating point estimates of iron 
concentration in each voxel within tumour ROIs through all voxels in the tumour that 
exhibit MRI signal changes upon cell injection. This semi-quantitative approach (22) 
estimates the ROI iron mass (M[Fe]) for inhomogeneous iron distributions within the 
tumour, by weighting each voxel per its negative log intensity ratio (a proportionate 
estimate of iron concentration): & '( = − +, --./0123 ×[ 56789:1356789;<;2=] (1) 
The natural log of each histogram bin’s signal value (I) is divided by the median 
signal value of the whole tumour ROI (Imedian). This value is multiplied by the normalized 
bin size, i.e. number of voxels in that bin (Voxelbin), divided by total number of voxels 
within the tumour ROI (Voxeltotal), resulting in a relative mass of iron M[Fe] for each bin.  
For lymph nodes, we used the M[Fe] integrated over the left side of the intensity 
distribution (i.e. all intensities less than the median intensity), hereafter represented as 
M[Fe]median. For tumours, due to the increased heterogeneity, and to increase the likelihood 
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that only voxels with iron-labelled cells are considered, M[Fe]s were summed over only 
the lowest 10% of the intensity distribution. This value is hereafter represented as M[Fe]10. 
Use of M[Fe]10 for lymph nodes was not practical due to their small size and fewer voxels. 
All M[Fe] values were then compared to baseline (i.e. pre-iron injection) to determine the 
% increase in M[Fe] at 24 and 48 hours post-injection. 
Statistical correlation analyses were done in Prism 6 (GraphPad Software) post-
hoc. SPSS (IBM analytics) was used to do a mixed ANOVA to evaluate the M[Fe]10 for 
each cell type over time and to evaluate the change in LN intensities. One-way ANOVAs 
were used to compare M[Fe]10 for untreated vs vaccinated mice at 24 hours post-cell 
injection.  
 
Immunohistochemistry. All mice used for immunohistochemistry were terminated at 24 
hours post-injection (separate group of mice from MRI). Transgenic C57BL/6 UbC-GFP 
mice were used as donor mice and normal C57BL/6 mice were used as recipients with 
tumour implants and vaccination done as described previously. Cryosectioning of tissues 
was performed at -20°C with 5 µm thickness.  An hour after sectioning, the tissues were 
rehydrated in PBS and fixed in 4% PFA for 15 minutes.  Tissues were washed 3x in PBS 
and incubated in block (0.1% BSA in PBS) for 30 minutes.  Tissues of mice that received 
either MDSC or CTL cell injections were incubated with either Ly-6G (Gr-1)-efluor660 or 
CD8α-efluor660, respectively, at 1:200 in block for 1 hour at 4oC. Tissues of mice that 
received Treg cells injections were first permeabilized in 1X permeabilizing solution for 
10 min, and then incubated in FoxP3-APC at 1:100 in block for 1 hour. After staining, 
slides were washed 3x in PBS and mounted with Fluoromount-G containing DAPI 
(eBioscience). 
 
Fluorescence confocal microscopy. Tissues were visualized using a Zeiss LSM 710 laser 
scanning confocal microscope (Carl Zeiss SBE, LLC) equipped with an XBO 50W lamp 
for DAPI fluorescence (lex 365, lem 420 nm), an Argon laser for GFP fluorescence (lex 
488 nm) equipped with a 515-565 band pass filter, and a HeNe laser for 548 and 633 nm 
excitation equipped with a low pass filter at 590 nm.  All images were acquired using 4 
averages per pixel at 1-1.5 A.U., a pixel dwell time of 6.30 µsec, 1024×1024 resolution, 
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on 0.9-1.2 µm slices. Nuclei were stained with DAPI (a stain that binds strongly to DNA) 
were used to visualize tissue morphology. Identification of cells within tumours from 
adoptive transfers was determined by overlay of GFP, Rhodamine B and the cell type 
identification (Gr-1-efluor660 for MDSCs, CD8α-efluor660 for CTLs or FoxP3-APC for 
Tregs) signals.  Images were visualized and processed using FIJI (ImageJ, NIH) (55). 
 
Results 
Cell culture, labelling and purity. Cell purity was assessed by FACS before incubation 
with SPIO to ensure >80% purity. CTLs were >80% pure (Supporting Fig. S1A), with 
~11% of the cell population identified as APCs (CD11c+) used for cell activation during in 
vitro expansion. The suppressive cell populations CD4+CD25+FoxP3+ Tregs and Gr-
1+CD11b+ MDSCs were at >80% purity after cell isolation and culture (Supporting Fig. 
S1B and C). Cell suppression assays were performed to determine the suppressive nature 
of both the MDSCs and Tregs (Supporting Fig. S2 for Tregs, see (43) for previous 
evaluation of the MDSCs used in this experiment – cells for both experiments were 
prepared and evaluated at the same time in 2014). Both cell types were successfully able 
to suppress cellular proliferation of responder T cells. Labelling cells with SPIO did not 
significantly affect cellular viability as assessed by trypan blue before cell injection. Iron 
loading levels, determined by the Prussian blue iron assay, were between 3-5 pg iron/cell 
for CTLs, between 5-7pg iron/cell for Tregs and approximately 30 pg iron/cell for MDSCs.   
 
Tumour growth. For this study we chose to administer the immunotherapy at a later time 
point than previous cancer studies with DPX-R9F (22,56,57) such that there would be some 
response from the therapy, but not complete tumour remission. As seen in Fig. 1A, 
vaccinating at 15 days post-implant resulted in tumours that were statistically significantly 
smaller than untreated controls on study day 31 (p<0.001, two-tailed student t-test). Mice 
injected with MDSCs had significantly larger tumours than mice injected with Tregs 
(p<0.05, multiple comparison t-tests), but not significantly larger than mice injected with 
CTLs (Fig. 2B) in the vaccinated group. It is possible there may have been some difference 
in vaccine efficacy driving decreased tumour volumes in mice receiving MDSCs vs Tregs, 
as experiments were done at different times and vaccinated from different vaccine batches. 
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There was no significant difference in tumour volumes in vaccinated mice that received 
CTLs compared to Tregs. In untreated mice, there were no significant differences in tumour 
volumes regardless of cell type that was injected. 
 
Immunohistochemistry. To differentiate between injected cells and innate/cancer cells, 
C57BL/6 UbC-GFP transgenic mice were used as donor mice and cells isolated from donor 
mice were injected I.V. into non-transgenic C57BL/6 diseased matched mice.  All 
protocols were performed the same otherwise.  The mice receiving cell injections were 
terminated 24 hours post-cell injection to maximize GFP+ and SPIO-rhodamine B 
fluorescence. Validation of recruitment of SPIO-labelled cells to tumours was performed 
by co-localizing rhodamine B fluorescence from the SPIO nanoparticles with GFP+ signals 
from the injected CTLs, Tregs or MDSCs cells (Fig. 2).  As a third verification, cell specific 
fluorescent antigens were used to label either CTLs (CD8+), Tregs (FoxP3), or MDSCs 
(Gr-1).  As expected, both GFP and rhodamine B fluorescence perfectly co-localize for 
each cell type, indicating adoptively transferred cells injected I.V. did localize to tumours, 
and can be located amongst surrounding tumour cells.   
 
Qualitative Descriptions of MR images. All tumours were implanted at the same location, 
however due to individual growth variability within mice, tumours may appear to be placed 
slightly different. Additionally, images in Figs. 3, 4 & 5, have been zoomed in to focus on 
tumours. Localized regions of hypointensities were observed approximately 24 hours after 
CTL injections, indicating the presence of SPIO-labelled cells in the tumours of both 
untreated and vaccinated mice (Fig. 3). In untreated mice, cells were mostly concentrated 
at the tumour periphery. However, there were instances of cells localizing further centrally 
within the tumour (Fig 3; arrows). In vaccinated mice, clusters of hypointensities were 
located both at the tumour periphery and in central regions. At 48 hours post-cell injections, 
hypointense regions disappeared from the tumour, which indicated that either cells are 
clearing from the tumour or that SPIO nanoparticles within the cells are undergoing 
degradation via the lysosomal pathway (58). CTL recruitment to the LNs was visibly 
apparent 24h post cell injection (Fig. 6). 
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 Suppressive SPIO-labelled MDSCs preferentially localize throughout the tumour 
in untreated mice as indicated by strong hypointense regions 24h post cell injections (Fig. 
4). MDSCs remain visible for 48h post-injection and iron generally begins to clear 72 hours 
post-injection. In contrast to the untreated group, three of four vaccinated mice lacked 
hypointensities, implying that recruitment is scarce within the tumour microenvironment 
in this group.  Only one vaccinated mouse in the group displayed hypointensities 
demarcating cells. There was no observed MDSC recruitment to LNs in both treated and 
untreated mice, reflected by no large change in signal intensity from images acquired 
before/after MDSC injection. This was not unexpected since MDSCs preferentially 
migrate to the tumour microenvironment (59). 
 As with MDSCs, Tregs were recruited to the tumour. Recruitment was visualized 
as hypointense regions throughout the tumour 24h post-cell injection in untreated mice 
(Fig. 5) and iron started clearing by 48h. Minimal hypointensities were detected in 
vaccinated mice throughout the tumour both 24 and 48 hours post cell injection, indicating 
minimal recruitment. Noteworthy, one of the four vaccinated mice injected with SPIO-
labelled Tregs underwent complete remission with no detectable tumour at day 27; 
therefore, mapping the migratory patterns of Tregs for this mouse was not possible.  As 
with CTLs, Tregs were abundantly recruited to lymph nodes and the iron persisted up to 
144 hours (Fig. 6).  
 
Semi-quantitative analysis of SPIO-labelled cells in LN. Signal intensity distributions 
were analysed in the form of histograms and used to semi-quantitatively analyse the 
recruitment of CTLs, Tregs, and MDSCs at 24 and 48 hours post cell-injection compared 
to baseline. Only voxels within lymph nodes having signal intensities less than the median 
were used for quantitation (M[Fe]median; equation 1) since it was deemed a more accurate 
representation of SPIO-labelled cell number and best characterized the MR image, 
particularly given the small size of the lymph nodes which prevented the use of a smaller 
portion of the distribution. The vaccine-draining lymph is the right inguinal lymph node, 
whereas the tumour draining lymph node is the left inguinal lymph node. Relative to 
unvaccinated mice, vaccinated mice showed trends of increased mean recruitment of CTLs 
and decreased mean recruitment of Tregs in both the tumour-draining and vaccine draining 
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inguinal LNs (Fig. 7; images in Fig. 6). Although the means were different, they were not 
statistically significant. There were no quantifiable signal changes in LNs for mice 
receiving MDSC injections. 
 
Semi-quantitative analysis of SPIO-labelled cells in tumours. Tumour mean signal 
intensity is not reflective of total iron content due to its continuously changing 
heterogeneous environment and therefore intensity histograms of tumour ROIs were 
extracted and used to filter out high intensity features (i.e. edema). As with lymph nodes, 
signal intensity distributions within the tumour were analysed in the form of histograms. 
Due to a larger number of voxels within tumours, those voxels having the lowest 10% of 
signal intensities were used for quantitation (M[Fe]10; equation 1) and results at 24 and 48 
hours were again compared to M[Fe]10 values at baseline.  
Vaccinated mice injected with CTLs had an overall higher M[Fe]10 than untreated 
mice (Fig. 8E) using our semi-quantitative analysis. Although the means seem to visually 
differ between treated and untreated mice, the large individual variability makes it 
statistically insignificant. However, the mean Treg M[Fe]10 value in vaccinated mice was 
significantly lower than untreated mice by one-way ANOVA at 24 hours post cell-
injection (p-value < 0.05) (Fig. 8C). The mean MDSC M[Fe]10 in untreated mice was 
statistically significant at 48h (p-value < 0.1) but not 24h (p-value > 0.1) post cell 
injection by one-way ANOVA (Fig. 8A). We have generally found that iron signal in 
tumours from MDSC recruitment seems to peak at 48 hours post-cell injections, whereas 
for Tregs and CD8s, the iron signal peaks at 24 hours. This is likely due to differences in 
cellular infiltration and division rates between different cell types (MDSCs are fully 
differentiated cells and are not likely to divide and proliferate in vivo). 	
Individual mouse correlations were made between tumour size and M[Fe]10 for 
MDCSs, Tregs and CTLs (Fig. 8B, D, E). SPIO-labelled MDSC M[Fe]10 showed a 
statistically significant positive correlation with final tumour volume (r = 0.8226, p-value 
< 0.01) (Fig. 8B) 24h post-injection. Recruitment of SPIO-labelled Tregs showed a 
statistically significant positive correlation with final tumour volume (r = 0.6113, p-value 
< 0.1) at the 24h post-injection time point (Fig. 8D). This implies an increase in recruitment 
of MDSCs and Tregs (as measured by M[Fe]10) with increasing tumour size for both 
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untreated and vaccinated mice. CTL recruitment was very weakly negatively correlated 
with increasing tumour size (one outlier was removed according to Grubb’s statistical test 
(60) in Prism 6 (Fig. 8F)), but there was no statistical significance. 
 
Discussion 
 This work demonstrates the possibility to monitor and measure semi-quantitative 
changes in the migration of CD8+ cytotoxic T cells, regulatory T cells and myeloid derived 
suppressor cells in tumour bearing mice following treatment with the vaccine based 
immunotherapy DepoVax™ (DPX). The presented technique is a potentially valuable tool 
for gaining a better understanding of underlying biological mechanisms in vivo in response 
to immunotherapies in preclinical studies. Isolated SPIO-labelled cells cultured in vitro 
were visualized by MRI as early as 24h post-cell injection (Figs. 3 to 6) and iron was 
cleared approximately 72h post-injection. Vaccination with the peptide-based vaccine 
DPX-R9F, as seen by the semi-quantitative metric for iron mass, M[Fe]10, caused a 
decrease in MDSC and Treg recruitment and a small increase in CTL recruitment in 
tumours (Fig. 8), albeit one that was non-significant. CTLs were recruited to both tumour 
and vaccine draining inguinal LNs, particularly for vaccinated mice (Fig. 7A and B). 
However the difference between vaccinated and control mice was not significant. Treg 
recruitment decreased to both inguinal LNs with vaccination (Fig. 7C and D).  These data 
are consistent with previously published data using the cervical tumour model (12,43,61).  
We have clearly demonstrated that vaccination with the DPX-R9F formulation decreases 
the recruitment of suppressive cells types (MDSCs and Tregs) to the tumour and mildly 
increases the immune system’s first line of defence: CTLs.  
 MRI immune cell tracking is a powerful technique for monitoring treatment 
efficacy due to its sensitivity in detecting individual variations in response to therapy. An 
increase in MDSC and Treg recruitment was evident 24h post-injection between vaccinated 
and untreated mice but also at an individual level, positively correlating tumour size to 
cellular recruitment within the tumour regardless of treatment (Fig. 8A, C). These results 
were expected given that larger, more advanced stage tumours are more effective in 
recruiting suppressive immune cells (62). This is likely one of the main reasons why 
vaccinated mice have significantly fewer Tregs and MDSCs. Additionally, previously 
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published work (12,61) has described that vaccination with DPX caused a significant 
decrease in MDSCs and Tregs in the spleen and blood of tumor bearing mice (measured 
using FACS) as well as within tumors (via immunohistochemistry). 
The difference in CTL recruitment to the tumour was minimal for vaccinated mice 
compared to untreated mice at both time points (Fig. 8E). The mean increase observed in 
Fig. 8E was strongly influenced by one mouse and recruitment to the tumour did not appear 
to depend on tumour size. There were large variations within vaccinated mice; some had 
barely detectable CTL cell recruitment, some exhibited small amounts of CTL recruitment 
(15-20% increase in M[Fe]10), and one mouse had an extremely large increase in M[Fe]10 
(147%). This observed variability is not uncommon given that a hallmark of 
immunotherapy is individual variation (63). This sensitivity to individual-level variability 
may be beneficial for determining and predicting individual responses to therapy. It is also 
possible that the chosen 4 weeks post-implant time point may not have been optimal for 
monitoring CTL migration to the tumour, particularly in response to treatment.   
Vaccination resulted in a large increase in CTL recruitment to both inguinal LNs. 
Recruitment to the vaccine-draining LN (Fig. 7A) was expected due to the vaccine-driven 
immune response (22). In this response, the antigen presenting cells bring antigens from 
the vaccination site to the LNs for presentation to T cells like CTLs (22).  Increased 
recruitment in the tumour-draining LN (Fig. 7B) likely indicates an active immune 
response to tumour cells or tumour cell antigens that may already be present in the tumour-
draining LN.  
Interestingly, although vaccination did cause a small increase in CTL recruitment 
to tumours and LNs, it was not the significant increase that might be expected. A potential 
explanation for this is likely related to the functionality of these CTLs. Prior to injection, 
these cells have been activated and primed to be cytotoxic effector CD8+ T cells. However, 
once they are injected, they are subject to the same environment as host cells, particularly 
the extremely suppressive tumour microenvironment. In this case, CTLs in the vaccine 
group may be more successful at retaining their functionality as cytotoxic cells, whereas 
CTLs injected into control mice become dysfunctional. Previous work (64) demonstrated 
that genes linked to clonality and cytotoxic activity were upregulated in cytotoxic T cells 
in response to therapy, but actual cell numbers remained unchanged. As indicated by the 
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decreased recruitment of suppressive cells (both Tregs and MDSCs) in vaccinated mice, 
the tumour microenvironment will likely affect functionality differently in each group, 
which is unfortunately not detectable with MRI cell tracking. Additional antigen 
presentation will also occur in vaccinated mice due to the presence of sustained antigen 
release. Previous publications (12, 61) have also speculated that it is the interplay of 
regulatory and effector T cells which will drive success vaccine responses, as opposed to 
solely CTL activity alone.  
Although the use of MRI cell tracking with SPIO has a tremendous amount of 
potential for studying immune responses to therapy, there are currently some important 
limitations. Hypointensities associated with iron oxide are not specific to SPIO. Tumours 
are notoriously heterogeneous: necrosis is a source of negative contrast and edema is a 
source of positive contrast with this pulse sequence. Attempts to compensate for these 
discrepancies were made by ensuring that hypointensities of interest were not present in 
baseline images and also cleared by three days post-injection. Contrary to SPIO-labelled 
cells, necrotic regions remain hypointense and persist past the 72h time point observed in 
this study. However, for longitudinal studies, adding additional baseline and follow-up 
scans is both time and resource-intensive. Using the lowest 10% of the intensity 
distribution in the semi-quantitative technique herein as representative of iron 
concentration is empirically reasonable but still somewhat arbitrary. Additionally, for later 
timepoints, particularly 48 hours and 72 hours, it is unclear as to whether cells are actually 
1) clearing from the tumour, 2) dividing, thereby diluting the visible iron, or 3) the iron is 
degraded within lysosomes and is no longer superparamagnetic. More quantitative imaging 
techniques are necessary to provide more accurate data, which would allow better 
understanding of individual-based differences, although there still would be limitations 
related to assessing functionality of cells necessitating the addition of histology and flow 
cytometry.  
Specificity and quantitation issues can be overcome by the use of fluorinated 
cellular labelling agents (29,65-68). Previous studies have used fluorine cell labelling for 
several different cell types administered as an external cell-based therapy (i.e. dendritic 
cells (31,65), stem cells (67)) or to label macrophages to study inflammation (29). Fluorine 
labelled cells can be detected with precise specificity using specialized surface coils or 
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dual-tuned hydrogen/fluorine coils. Fluorine-based MRI cell tracking can also yield 
quantitative information (29,67,68). Unfortunately, fluorine MRI is less sensitive than 
conventional proton MRI, making it difficult to detect smaller numbers of labelled cells, 
particularly at lower field strengths. It also requires more specialized equipment not 
necessarily available in all imaging facilities.  
Quantitative information can also be obtained by using a pulse sequence like 
TurboSPI (69,70). Originally designed for imaging water in porous media that have long 
R2* values but short R2 values, Rioux et al. demonstrated that TurboSPI could also be 
applied to SPIO-labelled cells, which exhibited similar magnetic properties (69). Although 
TurboSPI traditionally requires long data acquisition times, the sequence was greatly 
accelerated for in vivo use by adding compressed sensing reconstruction (70). It is possible 
to extract R2* maps from TurboSPI, which when combined with in vitro iron loading data, 
allows generation of cellular density maps. Although not specific to iron, R2* maps allow 
the distinction between iron-labelled cells and other causes of tissue heterogeneity, such as 
necrosis, based on the voxel time courses (69).  
We are currently working to implement TurboSPI and evaluate the use of R2* and 
cellular density maps to monitor migration of CTLs and Tregs in response to several 
immunotherapies. It will be particularly important to research variations in individual 
responses to determine if the use of MRI as an immune cell tracking device can yield 
important information on individual responses to immunotherapy, and more importantly, 
provide insight into optimal therapy combinations. 
Although this study was mainly designed as a proof of principle for tracking CTLs, 
Tregs and MDSCs in response to therapy, it will be particularly interesting to apply this 
technique to multiple time points, particularly to capture differences in cell migration in 
response to treatment over time. The longitudinal changes in immune behaviour in 
individual mice could potentially be linked with newer biomarkers such as LN swelling 
(56) and the immune-related response criteria (71) or iRECIST (72), as well as tumour 
volumes at the end of study.  
 
Conclusion 
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 This work demonstrates that MRI cell tracking can be used to monitor immune cell 
migration for various cell types in a cancer model in response to treatment with a peptide-
based vaccine immunotherapy. MRI cell tracking has immense potential as a preclinical 
tool to increase our understanding of in vivo longitudinal dynamics of various immune 
populations in response to many immune therapies currently under development. Most 
importantly, it is possible to study changes in immune cell recruitment in individual mice 
over time, potentially allowing improved application and combination of therapies that can 
then be translated to the clinic.  
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Figure Captions 
 
Figure 1 – Final Tumour Volumes. Final tumour volumes at study day 31 were measured 
with calipers. There was a statistically significant difference between untreated and 
vaccinated mice (unpaired student T-test, p<0.0001). There was no significant difference 
between untreated groups, regardless of cell type injected. For vaccinated mice, mice that 
received MDSC injections had significantly larger tumour volumes than mice that received 
Treg injections, but were not significantly larger than mice that received CTL injections. 
 
Figure 2 – Immunohistochemistry of SPIO-Labelled Cells in Tumours. D) Laser scanning 
confocal microscopy characterization of 5 µm C3 tumour tissues sections ~29 days post 
C3 implant and 1 day post cell injection. Injected cells were GFP+ under the control of the 
ubiquitin C promoter (green) and labelled with SPIO rhodamine B nanoparticles (red). 
Tissues were labelled with a cell-specific antigen (yellow): Tregs = FoxP3-APC, CTLs = 
CD8a-efluor660, and MDSCs = Gr-1-efluor660. All tissues were embedded with 
Fluoromount-G containing DAPI (blue). The scale bars represent 25 µm. 
 
Figure 3 – Representative bSSFP MR Images of tumours from Mice that Received SPIO-
labelled CD8+ cytotoxic T Cell Injection. Top row is representative of untreated mice and 
bottom row of vaccinated mice. Images are from baseline (pre-injection), 24 hours, and 48 
hours post-injection. In both untreated and vaccinated mice there is a large amount of CTL 
recruitment to both the periphery of the tumour and the tumour core (arrows) with 
hypointensities beginning to clear by 72 hours (data not shown). At baseline, mouse 
positioning causes the tumour to appear shifted posteriorly, however images are displaying 
the same central region for all days. L – left, R – right.  
 
Figure 4 – Representative bSSFP MR Images of tumours from Mice that Received SPIO-
Labelled MDSC Injection. Top row is representative of untreated mice and bottom row of 
vaccinated mice. Images are from baseline (pre-injection), 24 hours, and 48 hours post-
injection. In untreated mice there was a large amount of MDSC recruitment throughout the 
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tumour (arrows), with hypointensities beginning to clear by 72 hours. MDSC recruitment 
was minimal in vaccinated mice. L – left, R – right.  
 
Figure 5 – Representative bSSFP MR Images of Tumours from Mice that Received SPIO-
Labelled Treg Injection. The top row is representative of untreated mice and the bottom 
row of vaccinated mice. Images are from baseline (pre-injection), 24 hours, and 48 hours 
post-injection. In untreated mice there is a large amount of Treg recruitment throughout 
the tumour (arrows), with some hypointensities clearing by 48 hours. Treg recruitment was 
decreased in vaccinated mice. L – left, R – right.  
 
Figure 6 - Representative bSSFP MR Images of LNs from Mice that Received SPIO-
Labelled CTL or SPIO-Treg Injections. Hypointensities in LNs represent CTL or Treg 
recruitment at 24h, 48h and 72h (CTLs) or 144h (Tregs).  L – left, R – right. 
 
Figure 7 – Semi-Quantitative Assessment of T Cell Recruitment to Inguinal LNs. 
Recruitment of either CTLs (A, B) or Tregs (C, D) to vaccine-draining inguinal LN (A, C) 
and tumour-draining inguinal LN (B, D) using the M[Fe]median as a metric. Vaccinated mice 
had increased recruitment of CTLs to both inguinal LNs and decreased recruitment of 
Tregs but differences were not statistically significant. Error bars represent standard error. 
 
Figure 8 - Semi-Quantitative Assessment of Cell Recruitment in Tumours and Correlation 
of Immune Cell Recruitment (Using M[Fe]10) and Final Tumour Volume. 
Recruitment of MDSCs (A, B), Tregs (C, D), and CTLs (E, F) to the tumour using M[Fe]10 
as a metric. Vaccinated mice demonstrated decreased recruitment of MDSCs and Tregs to 
the tumour and increased recruitment of CTLs to the tumour. Significance judged using 
one-way ANOVA. Error bars represent standard error. Correlation of MDSC (B), Treg (D), 
or CTL (F) recruitment 24 hours post-injection with final tumour volume. Both MDSC and 
Treg recruitment (M[Fe]10) was positively correlated with the final tumour volume. CTL 
recruitment (M[Fe]10) was negatively correlated with final tumour volume but correlation 
was not significant. Dotted curved lines represent 95% confidence intervals. One outlier 
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was removed from CTL correlation graph using Grubbs statistical outlier test. * represents 
p<0.1, ** p<0.05. 
 
Supporting Figure S1. Cell Purity of Isolated Cells. Flow cytometry culture purity analysis 
for CTLs (A), Tregs (B) and MDSCs (C). Analysis was done immediately prior to iron 
labelling.  Cells were gated for live cells and are representative of the full cell injection.  
CD11c control demonstrates that a small proportion (~10%) are APCs due to addition of 
APCs to culture for in vitro stimulation of T cells. FoxP3+ cells were first gated for 
CD4+CD25+. 
 
Supporting Figure S2 - Treg Supression Assay.  Treg-mediated suppression was measured 
using the cell proliferation dye efluor670 (eBioscience) at 0.5 µM.  CD4+ T cells (Tresp) 
were isolated from tumour-bearing C57BL/6 mice, incubated with efluor670, and activated 
using CD28 antibody on a plated CD3+ 96-well plate.  Tregs were isolated from transgenic 
GFP+ mice. Tresps were cultured either alone (blue) or in the presence of Tregs at a 1:1 
ratio (red).  Cells were cultured for 72 hours and proliferation was determined by flow 
cytometry analysis gating for GFP- efluo670+ cells.  Tresp stimulation was confirmed by 
comparison to Tresp fixed at 0h of incubation (black). 
 
Supporting Table S1 - Primary Antibodies and Sources. 
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Supporting Methods 
 Materials. Culture media (IDEM and RPMI-1640), phosphate buffered saline 
(PBS), gentamycin, L-glutamine, 2-mercaptoethanol, penicillin-streptomycin (Pen-Strep; 
10 000 U/mL), Hank’s Buffered Salt Solution++ (HBSS++) were obtained from Gibco. 
Fetal calf (FCS) and fetal bovine (FBS) serums were obtained from Seradigm. 
Lipopolysaccharides (LPS), rapamycin, mitomycin-c, mouse IL-12, conc. hydrochloric 
acid (HCl), K4Fe(CN)6, paraformaldehyde (PFA), HEPES buffer, and bovine serum 
albumin (BSA) were obtained from Sigma. 10X permeabilizing buffer was obtained from 
eBioscience. SPIO nanoparticles (Rhodamine B Molday ION) were purchased from 
Molday, Biopal. C3 media was made by supplementing IMDM with 10% heat-
inactivated fetal calf serum, 2 mM L-glutamine, 50 mM 2-mercaptoethanol, 100 U/ml 
penicillin and 100 μg/ml streptomycin).  Complete RPMI media was made by 
supplementing RPMI-1640 with 10% FBS, 50 mM 2-mercaptoethanol, 100 U/mL 
penicillin and 100 μg/ml streptomycin. 
 All cell counts were performed using a hemocytometer and a cell dilution of 1:10 
in trypan blue.  
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Supporting Figure S1. Cell Purity of Isolated Cells. Flow cytometry culture purity 
analysis for CTLs (A), Tregs (B) and MDSCs (C). Analysis was done immediately prior 
to iron labelling.  Cells were gated for live cells and are representative of the full cell 
injection.  CD11c control demonstrates that a small proportion (~10%) are APCs due to 
addition of APCs to culture for in vitro stimulation of T cells. FoxP3+ cells were first 
gated for CD4+CD25+. 
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Supporting Figure S2 - Treg Supression Assay.  Treg-mediated suppression was 
measured using the cell proliferation dye efluor670 (eBioscience) at 0.5 PM.  CD4+ T 
cells (Tresp) were isolated from tumour-bearing C57BL/6 mice, incubated with 
efluor670, and activated using CD28 antibody on a plated CD3+ 96-well plate.  Tregs 
were isolated from transgenic GFP+ mice. Tresps were cultured either alone (blue) or in 
the presence of Tregs at a 1:1 ratio (red).  Cells were cultured for 72 hours and 
proliferation was determined by flow cytometry analysis gating for GFP- efluo670+ cells.  
Tresp stimulation was confirmed by comparison to Tresp fixed at 0h of incubation 
(black). 
 
 
 
